Skip to main content
2023 ACCP Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Yurong Lai, PhD

Executive Director, Drug Metabolism
Gilead Sciences Inc

Dr. Lai is currently Exec. Director of Drug Metabolism at Gilead Sciences. He is a Fellow of the American Association of Pharmaceutical Scientists and Adjunct Faculty in the University of Rhode Island Department of Pharmacy. His current role in Gilead is to manage and implement in vitro/in vivo preclinical and clinical strategies for compound advancement to regulatory filing. He received his M.D. from Fujian Medical University in China and his Ph.D. (Toxicology) from Sapporo Medical University in Japan in 1998. Before joining Gilead, Dr. Lai led research programs at Pfizer and BMS in transporter research and ADME-PK-Tox. He is the associate editor/editorial board member of top-ranking DMPK journals, including DMD, BDD, JPS, Frontier Pharmacology, etc. He authorizes a book, book chapters, and over 180 original publications.

Presentation(s):